Defensin Peptides vs SkinBetter Science®: An Honest Comparison
Both defensin-based and retinoid-based skincare technologies are used in clinical anti-aging practices, but they represent fundamentally different approaches — one introduces a new class of molecule, the other delivers known ingredients through a more sophisticated formulation.
Both technologies have published clinical evidence. Both are sold through dermatologists and medical spas. So what actually separates them?
SkinBetter Science® is built around formulation innovation. Its two proprietary platforms — AlphaRet® and InterFuse® — represent genuinely clever chemistry. AlphaRet bonds a retinoid to lactic acid (an alpha hydroxy acid) for controlled release and reduced irritation. InterFuse is a patented delivery system for hyaluronic acid and peptides. The underlying active ingredients — retinoids, AHAs, peptides, hyaluronic acid, antioxidants — are well-established. The innovation is in how they are combined and delivered.
DefenAge Age-Repair Defensins® are built around molecular innovation. Alpha-Defensin 5 and Beta-Defensin 3 are a new class of molecule that did not exist in topical skincare before DefenAge. They are bioidentical to innate immune peptides the human body naturally produces — fully synthetic, vegan, and patented exclusively for topical skincare use. Four published peer-reviewed clinical studies document visible improvements across the face, eye area, body skin, and post-procedure contexts.
SkinBetter makes known ingredients work more elegantly. DefenAge introduces ingredients the category has not had before. That is a meaningful distinction for anyone choosing between these two approaches.
For foundational context on how defensin peptides differ from retinoid-based approaches, see Defensin Peptides vs Retinol — the starting point for understanding the defensin difference.
SkinBetter Science has published clinical evidence for AlphaRet and InterFuse products — including a 48-subject, 12-week AlphaRet trial — showing visible improvement in wrinkles, lines, tone, and texture. These are real results from a real retinoid, delivered more tolerably than standard retinoids. DefenAge has four published peer-reviewed studies across three journals, including a multi-center, double-blind, vehicle-controlled trial (Taub et al, JDD 2018), documenting statistically significant visible improvement.
The core distinction is not about which technology works. Both do. It is about what kind of innovation each represents — and whether a more sophisticated retinoid formula addresses the same biological goals as a genuinely new class of regenerative peptide.
Two patented, lab-synthesized bioidentical peptides — Alpha-Defensin 5 and Beta-Defensin 3. A new molecule class exclusive to DefenAge, not previously available in topical skincare. Fully synthetic, vegan, no human- or animal-derived material. Four published peer-reviewed clinical studies across face, eyes, body, and post-procedure contexts.
AlphaRet® is a patented molecule that bonds a retinoid to lactic acid for controlled release with reduced irritation. InterFuse® is a patented delivery system for hyaluronic acid and peptides. Both are formulation innovations built on well-established active ingredient categories — retinoids, AHAs, cosmetic peptides, and hyaluronic acid.
The Published Clinical Evidence — Study by Study
Both technologies have published peer-reviewed clinical research. Here is what that research actually documents.
Multi-center, double-blind, vehicle-controlled trial
Participants using the DefenAge defensin regimen demonstrated statistically significant visible improvement in tone, texture, firmness, lines, and overall appearance versus vehicle control. Evaluation included clinical grading, histopathology, immunohistochemistry, photography, and ultrasound — a rigorously comprehensive methodology for a cosmetic study.
JDD 2018;17(4):426–441. PMID: 29601620
Periocular wrinkles — independent follow-up trial
An independent follow-up trial in which participants demonstrated significant visible improvement in periocular wrinkles with the enhanced-concentration defensin BioSerum versus control. Replication in a second independent published trial adds substantial support.
JDD 2023;22(9):874–880. PMID: 37683059
Eye cream trial — periocular rhytids
Published trial of the DefenAge 3D Eye Radiance Cream documenting visible improvement in periocular wrinkles and skin quality — extending defensin clinical evidence to a dedicated eye-area product.
J Cosmet Dermatol. 2020;19(8):2000–2005. doi: 10.1111/jocd.13424. PMID: 32614135
Body cream trial — skin composition
Published trial of the DefenAge 10 Luxe Hand and Body Cream documenting visible improvement in skin composition and quality — extending defensin clinical evidence to body skin.
J Cosmet Dermatol. 2023;22(2):620–627. doi: 10.1111/jocd.15118. PMID: 35621235
Microneedling with defensins vs microneedling with PRP — a published comparison
In this published pilot study, participants in the microneedling combined with defensins group demonstrated greater visible improvement in that study setting compared to participants in the microneedling combined with PRP group. This is relevant for anyone evaluating post-procedure skincare options — and supports the case that defensin technology has a documented post-procedure application alongside its daily anti-aging use.
Facial Plast Surg Clin North Am. 2018;26(4):447–454. doi: 10.1016/j.fsc.2018.06.006. PMID: 30213426
Defensins are also compared to other professional skincare platforms, including TriHex Technology® (ALASTIN) and SkinCeuticals® antioxidant science — each representing a different approach to visible skin renewal.
Key Differences at a Glance
| Category | DefenAge Age-Repair Defensins® | SkinBetter Science® AlphaRet® + InterFuse® |
|---|---|---|
| Type of innovation | Molecular innovation — a new class of bioidentical peptide not previously available in topical skincare | Formulation innovation — novel delivery of well-established active ingredient categories (retinoids, AHAs, cosmetic peptides, HA) |
| Active ingredient origin | New molecule class patented exclusively for topical use — no other brand can source or formulate with these peptides | Retinoids, AHAs, and Matrixyl 3000 peptides (Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7) — widely available from any cosmetic ingredient supplier, used in hundreds of products worldwide |
| Retinoid content | Not a retinoid product — works through a different biological pathway entirely | Built on retinoid science — AlphaRet is a retinoid bonded to lactic acid; the core mechanism is still vitamin A receptor-mediated cell turnover |
| Tolerability profile | In the Taub 2018 trial, defensin regimen was well tolerated in study participants including those who had not completed retinoid regimens | AlphaRet is designed for reduced retinoid irritation vs standard retinoids — a meaningful formulation improvement, though retinoid-related considerations remain |
| Published clinical trials | Four published peer-reviewed studies across face, eyes, body, and post-procedure contexts in three journals | Published clinical studies on AlphaRet (48 subjects, 12 weeks), InterFuse LINES (25 subjects, 8 weeks), and InterFuse Treatment Cream (52 subjects, 12 weeks) |
| Study methodology | Multi-center, double-blind, vehicle-controlled (Taub 2018) with histopathology, immunohistochemistry, photography, and ultrasound | Dermatologist-led clinical trials with published results; retinoid mechanisms supported by extensive prior literature |
| Ingredient exclusivity | Patents on the molecules themselves — the competitive moat is the ingredient, not the formula | Patents on AlphaRet (retinoid-AHA bond) and InterFuse (delivery system) — formulation processes are protected, but underlying ingredients are universally available |
| Ingredient origin | Fully synthetic, vegan, no human- or animal-derived material | Synthetic ingredients; no human-derived material |
| Hero product price | $198 (8-in-1 BioSerum) | ~$175–$225 (AlphaRet Overnight Cream / Intensive AlphaRet Overnight Cream) |
Four Meaningful Differences Worth Understanding
New biology vs better packaging of known science
Retinoids have been in clinical skincare since the 1970s. AHAs since the 1990s. Matrixyl 3000 peptides since the early 2000s. SkinBetter's genuine contribution is making these work together more elegantly — and that is a real achievement. But it is still the same biology. Defensin peptides introduce a biological mechanism that did not exist in topical skincare before DefenAge — a bioidentical molecule class the body already recognizes, delivered topically for the first time.
A retinoid alternative vs a better retinoid
AlphaRet is a more tolerable retinoid — it delivers the retinoid mechanism with less irritation by bonding it to lactic acid. That is a meaningful improvement for people who have struggled with standard retinoids. But it is still a retinoid, with retinoid-related considerations. Defensin peptides work through a completely different pathway — the innate immune signaling system, not vitamin A receptor activation. For people who cannot or prefer not to use retinoids at all, this is a substantive difference.
Exclusive molecules vs exclusive formulas
SkinBetter's patents protect how AlphaRet bonds a retinoid to lactic acid, and how InterFuse delivers ingredients. Those are proprietary processes. But Palmitoyl Tripeptide-1 (GHK) and Palmitoyl Tetrapeptide-7 — the peptides in SkinBetter's "targeted peptide blend" — are commodity ingredients available to any cosmetic formulator worldwide, used in drugstore and luxury products alike. DefenAge's patents cover the defensin molecules themselves. No other company can source, formulate, or sell these peptides for topical use.
Four published studies vs three product-specific trials
SkinBetter has published clinical data on specific products — AlphaRet, InterFuse LINES, and InterFuse Treatment Cream — showing visible improvement in wrinkles, tone, and texture. These are real results. DefenAge has four published peer-reviewed studies across three journals covering the face, eye area, body skin, and post-procedure contexts — including a multi-center, double-blind, vehicle-controlled trial that is among the most rigorously designed published studies in cosmetic skincare research.
The Retinoid Alternative Question
This is where the comparison between these two technologies is most practically relevant for many consumers.
SkinBetter's AlphaRet is designed to be a better retinoid — one that delivers retinoid results with less irritation by controlling the release of the active molecule. For people who want retinoid science but have found standard retinoids too irritating, AlphaRet represents a genuine improvement in tolerability.
DefenAge is not a retinoid product at all. It works through a different biological pathway. In the Taub et al 2018 trial, the defensin regimen was well tolerated in study participants — including those who had not completed retinoid regimens — while demonstrating statistically significant visible improvement. The 2023 Hartman et al trial independently documented similar tolerability findings.
The practical question is this: are you looking for a more tolerable retinoid, or are you looking for an alternative to retinoid science entirely? If the former, SkinBetter's AlphaRet addresses that directly. If the latter — particularly for people with sensitive skin, rosacea, or a compromised barrier who want clinical-grade visible improvement without any retinoid mechanism — DefenAge's defensin platform has the more directly relevant published evidence.
DefenAge may be right for you if:
- You want a retinoid alternative — not a better retinoid, but a different biological pathway entirely
- You have sensitive skin, rosacea, or cannot tolerate retinoids in any form
- You want a new molecule class that did not previously exist in topical skincare
- You want four published peer-reviewed studies across multiple product categories
- You want patented molecules exclusive to one brand — not a proprietary formula using commodity ingredients
- You want fully synthetic, vegan ingredients with no human- or animal-derived material
SkinBetter Science may appeal to you if:
- You want retinoid science delivered more tolerably than standard retinoids
- You have used standard retinoids and want a less irritating version
- You want a comprehensive skincare line from a single brand — cleanser, SPF, moisturizer, treatments
- Your dermatologist has specifically recommended AlphaRet or InterFuse for your skin goals
SkinBetter Science makes genuinely well-formulated products. AlphaRet is clever chemistry — bonding a retinoid to lactic acid for controlled release is a real formulation achievement, and the published clinical data supports its visible improvement claims. For people who want retinoid science with less irritation, it is a legitimate choice.
DefenAge represents a different kind of proposition entirely. It is not a better retinoid — it is a technology that works through a biological pathway retinoids cannot access, using patented molecules that are exclusive to one brand, backed by four published peer-reviewed studies including a multi-center, double-blind, vehicle-controlled trial.
The question is not which technology is more sophisticated. Both are. The question is whether you want a more elegant version of established science, or a genuinely new class of molecule with its own published clinical evidence base.
What Dermatologists Have Said About Defensin Technology
"The science is remarkable. For patients who previously couldn't tolerate retinoids, the visible results I've seen with defensin technology have been genuinely impressive."
Amy Taub, MD Lead author, Taub et al JDD 2018; co-investigator, Hartman et al JDD 2023
"For patients with sensitive skin or rosacea who need effective anti-aging without retinol irritation, this is the alternative I reach for. It delivers visible results without the trade-offs."
Melda Isaac, MD Board-Certified Dermatologist, Washington DC
"Defensins represent a new era in skin rejuvenation. The approach is genuinely distinct from growth factors, retinoids, and standard peptide categories — it belongs in its own class."
Gregory Keller, MD Principal Investigator, Taub et al 2018; Berens et al 2020; Eggerstedt et al 2023
Frequently Asked Questions
Is DefenAge the same as SkinBetter Science AlphaRet?
No — they represent different categories of skincare technology. SkinBetter's AlphaRet is a retinoid bonded to lactic acid — a formulation innovation designed to deliver retinoid science more tolerably. DefenAge uses patented bioidentical defensin peptides — a new molecule class that works through a different biological pathway and did not exist in topical skincare before DefenAge. Both have published clinical evidence; they address different needs.
What makes AlphaRet different from regular retinoids?
AlphaRet is a patented molecule that chemically bonds a retinoid to lactic acid (an alpha hydroxy acid). This controlled-release formulation is designed to reduce the irritation associated with standard retinoids — redness, peeling, and sun sensitivity — while maintaining retinoid efficacy. Published clinical data on AlphaRet shows visible improvement in wrinkles, tone, and texture. It is a meaningful formulation improvement over standard retinoids. The core mechanism, however, is still vitamin A receptor-mediated cell turnover — retinoid science delivered more elegantly.
Can I use DefenAge instead of AlphaRet?
If your goal is a more tolerable retinoid, AlphaRet and DefenAge address that need differently. AlphaRet reduces retinoid irritation through formulation chemistry. DefenAge is not a retinoid at all — it works through a completely different pathway. In the Taub et al 2018 trial, the defensin regimen was well tolerated in study participants including those who had not completed retinoid regimens, while demonstrating statistically significant visible improvement. For people who want retinoid-free visible improvement, DefenAge has the more directly relevant published evidence.
Are SkinBetter's peptides the same as DefenAge's peptides?
No — they are different categories of peptide science. SkinBetter's "targeted peptide blend" consists of Palmitoyl Tripeptide-1 (GHK) and Palmitoyl Tetrapeptide-7 — the combination known as Matrixyl 3000. These are widely used cosmetic peptides available from any ingredient supplier, present in hundreds of products across all price points. DefenAge's Alpha-Defensin 5 and Beta-Defensin 3 are patented for topical skincare use — no other company can source or formulate with these specific peptides. They are a different biological class entirely.
Does SkinBetter have clinical evidence for its products?
Yes — SkinBetter has published dermatologist-led clinical trials on AlphaRet (48 subjects, 12 weeks), InterFuse LINES (25 subjects, 8 weeks), and InterFuse Treatment Cream (52 subjects, 12 weeks), showing visible improvement in wrinkles, lines, tone, texture, and firmness. These are real published results. DefenAge has four published peer-reviewed studies across three journals — including a multi-center, double-blind, vehicle-controlled trial — covering the face, eye area, body skin, and post-procedure contexts. Both technologies have published clinical evidence; the methodology and breadth of contexts covered differ.
How is DefenAge different from other peptide skincare products?
Most cosmetic peptides — including Matrixyl 3000, argireline, and similar widely used peptides — are commodity ingredients available to any formulator. They appear in products across all price points and have been used in skincare for decades. DefenAge's defensin peptides are a different biological class: bioidentical versions of innate immune molecules naturally produced by the human body, patented exclusively for topical skincare use. No other brand has access to them. This is the distinction between a well-formulated product using available ingredients and a product built on an exclusively owned molecular platform.
Can I use DefenAge alongside a retinoid or AlphaRet?
DefenAge is designed to layer with other skincare technologies, including retinoids and retinoid-based products. Because defensin peptides work through a different biological pathway, they can complement rather than duplicate retinoid activity. This makes DefenAge relevant both as a standalone retinoid alternative and as an addition to an existing retinoid-based routine. Specific layering decisions should be guided by your dermatologist or skincare provider based on your individual skin goals and routine.
Explore more comparisons
References & Further Reading
- Taub A, Bucay V, Keller G, Williams J, Mehregan D. "Multi-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen." Journal of Drugs in Dermatology. 2018;17(4):426–441. PMID: 29601620
- Hartman N, Loyal J, Taub A, Fabi S. "Clinical Trial of Alpha and Beta Defensin Skin Care Regimen for Improvement of Periocular Wrinkles." Journal of Drugs in Dermatology. 2023;22(9):874–880. doi: 10.36849/JDD.7184. PMID: 37683059
- Berens AM, Ghazizadeh S. "Effect of defensins-containing eye cream on periocular rhytids and skin quality." Journal of Cosmetic Dermatology. 2020;19(8):2000–2005. doi: 10.1111/jocd.13424. PMID: 32614135
- Eggerstedt M, Torres-Maldonado S, Danielian A, Hwang SHJ, Echanique KA. "Impact of defensins-containing body cream on skin composition." Journal of Cosmetic Dermatology. 2023;22(2):620–627. doi: 10.1111/jocd.15118. PMID: 35621235. PMCID: PMC10087582
- Duncan DI. "Microneedling with Biologicals: Advantages and Limitations." Facial Plastic Surgery Clinics of North America. 2018;26(4):447–454. doi: 10.1016/j.fsc.2018.06.006. PMID: 30213426
- Takahashi M, Umehara Y, Yue H, et al. "The Antimicrobial Peptide Human β-Defensin-3 Accelerates Wound Healing by Promoting Angiogenesis, Cell Migration, and Proliferation Through the FGFR/JAK2/STAT3 Signaling Pathway." Frontiers in Immunology. 2021;12:712781. doi: 10.3389/fimmu.2021.712781
- Shimizu Y, Nakamura K, Kikuchi M, et al. "Lower human defensin 5 in elderly people compared to middle-aged." GeroScience. 2022;44(2):997–1009. PMID: 34105106
- Grove GL, Kligman AM. "Age-associated changes in human epidermal cell renewal." Journal of Gerontology. 1983;38:137–142.
- DefenAge. "Peer-reviewed study confirming effectiveness of defensin-based BioSerum." View study summary
- DefenAge. "Physician testimonials and clinical perspectives." View testimonials
DefenAge products are cosmetic formulations intended to improve the appearance of the skin and are not intended to affect the structure or function of the body. This page is for cosmetic skincare education only and does not constitute medical advice. Physician quotes are sourced from publicly available DefenAge materials and used with permission. AlphaRet®, InterFuse®, and skinbetter science® are registered trademarks of skinbetter science — referenced here for comparison purposes only. Age-Repair Defensins® and DefenAge® are trademarks of Progenitor Biologics, LLC. Matrixyl® 3000 is a registered trademark of Sederma. Product prices are approximate and subject to change. Technology comparisons are based on publicly available ingredient information and peer-reviewed literature at time of publication. DefenAge makes no claims regarding the efficacy of competitor technologies.